Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IODIXANOL vs ORAGRAFIN CALCIUM
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Iodixanol is a nonionic, iso-osmolar iodinated contrast agent that attenuates X-rays, allowing visualization of vascular structures and organ parenchyma. It does not bind to or interact with specific receptors.
Oragrafin Calcium is a diagnostic radiocontrast agent that contains calcium ipodate. It acts by absorbing X-rays due to its high iodine content (61% iodine by weight). After oral administration, it is absorbed and excreted into the bile, allowing radiographic visualization of the gallbladder and biliary ducts. It may also enhance CT imaging of the liver and biliary tree.
FDA-approved: Intravascular contrast for computed tomography (CT) and angiography, including coronary angiography and left ventriculography,Off-label: Arthrography, hysterosalpingography, fistulography
Oral cholecystography and cholangiography for visualization of the gallbladder and biliary ducts,CT imaging of the liver and biliary system (off-label)
Intravenous injection of 270-350 mg iodine/kg (0.5-1.0 m L/kg of 270 mg I/m L solution) for CT; 300-400 mg iodine/kg for angiography. Administer as bolus or infusion per procedure.
Oral: 5 m L (1 packet) orally, may repeat in 30-60 minutes if needed. Maximum 2 doses per procedure. Rectal: 100-200 m L of a 1:1 dilution with water as a retention enema.
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 m L/min), half-life may be prolonged up to 10-12 hours, requiring dose adjustment and monitoring.
Terminal elimination half-life is 1.2 hours (0.7–2.0 hours) in patients with normal renal function. May be prolonged in renal impairment (up to 18 hours in severe impairment).
e GFR <30 m L/min/1.73m²: avoid use unless essential; if used, reduce dose by 50% and ensure hydration. e GFR 30-59: no dose reduction but ensure adequate hydration and consider lower dose per risk.
No specific dose adjustment required; use with caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of contrast-induced nephropathy. Consider alternative imaging if GFR <30.
Risk of hypersensitivity reactions, including anaphylaxis and death. Prophylaxis is not reliable. Emergency drugs and equipment must be available.
Iodixanol is a nonionic iodinated contrast agent. Limited human data; no evidence of teratogenicity in animal studies. Risk cannot be excluded; use only if clearly needed. First trimester: avoid unless essential due to theoretical risk of fetal thyroid suppression from free iodide. Second/third trimesters: minimal fetal exposure; consider fetal thyroid function if high doses or repeated exposure.
FDA Pregnancy Category D. First trimester: theoretical risk of fetal hypothyroidism from iodide exposure, avoid unless essential. Second and third trimesters: fetal thyroid suppression and goiter formation possible; use only if clearly needed with fetal thyroid monitoring.
Iodixanol is an iso-osmolar, nonionic iodinated contrast medium with lower nephrotoxicity than high-osmolar agents. Administer adequate hydration before and after procedure to reduce risk of contrast-induced acute kidney injury (CI-AKI). Screen for risk factors: pre-existing renal impairment (e GFR < 30 m L/min/1.73m²), diabetes mellitus, dehydration, concurrent nephrotoxic drugs. Have emergency equipment available due to risk of anaphylactoid reactions. Use lowest dose necessary for diagnostic image.
Oragrafin Calcium (ipodate calcium) is an oral cholecystographic agent used for gallbladder opacification. Calcium salt form may cause less diarrhea than sodium salt. Administer with a high-fat meal to stimulate gallbladder contraction and improve opacification. Patients with renal impairment may have increased risk of nephrotoxicity; ensure adequate hydration. Use caution in patients with hypercalcemia or calcium renal stones. May interfere with thyroid function tests; discontinue 1 week prior to thyroid studies.
No interactions on record
IODIXANOL and ORAGRAFIN CALCIUM are distinct pharmacological agents. IODIXANOL belongs to the Radiocontrast Agent class and is primarily used for FDA-approved: Intravascular contrast for computed tomography (CT) and angiography, including coronary angiography and left ventriculographyOff-label: Arthrography, hysterosalpingography, fistulography. ORAGRAFIN CALCIUM belongs to the Radiocontrast Agent class and is primarily used for Oral cholecystography and cholangiography for visualization of the gallbladder and biliary ductsCT imaging of the liver and biliary system (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. IODIXANOL carries a safety status of Category C, whereas ORAGRAFIN CALCIUM safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Iodixanol is not metabolized; it is excreted unchanged via glomerular filtration with minimal tubular reabsorption.
Oragrafin Calcium is not extensively metabolized; it is excreted primarily as unchanged drug in the bile and urine. A small fraction may undergo deiodination or conjugation in the liver.
Primarily renal: approximately 97% of the administered dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Less than 3% is excreted in feces via biliary elimination.
Primarily renal: 90% of absorbed dose excreted unchanged in urine within 24 hours; <10% via feces. Biliary excretion is negligible in the absence of hepatobiliary obstruction.
Negligible protein binding (<2%), primarily bound to albumin. This low binding minimizes interference with protein-dependent transport and reduces risk of drug interactions.
Negligible (<1% bound to plasma proteins).
Volume of distribution at steady state (Vdss) is approximately 0.26 L/kg (range 0.2-0.3 L/kg), suggesting distribution primarily in extracellular fluid. This low Vd indicates limited tissue penetration.
Approximately 0.5 L/kg, indicating distribution primarily into extracellular fluid.
Not applicable for oral route as iodixanol is only administered intravascularly (intravenous, intra-arterial). Bioavailability is 100% upon intravenous administration.
Oral: ~6% (low systemic absorption due to poor intestinal uptake; drug acts locally in GI tract).
No specific dose adjustments for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of adverse reactions; consider lower dose and monitoring.
No specific dose adjustment recommended for Child-Pugh class A, B, or C. Use with caution in severe hepatic impairment due to potential alterations in bile acid metabolism.
Intravenous: 1.0-2.0 m L/kg of 270 mg I/m L solution (270-540 mg iodine/kg) for CT; adjust for procedure and body weight; maximum total dose not established; repeat dosing with caution.
Neonates and infants: 1-2 m L/kg orally as a single dose. Children: 2.5-10 m L orally based on age (2-5 years: 2.5-5 m L; 6-12 years: 5-10 m L). Maximum 10 m L per dose.
No specific dose adjustment, but consider age-related renal impairment; assess e GFR and avoid in severe renal dysfunction; ensure adequate hydration pre- and post-administration.
No specific dose adjustment; use lower end of dosing range (5 m L orally) due to increased risk of dehydration and contrast-induced nephropathy. Ensure adequate hydration.
No FDA black box warning is currently associated with Oragrafin Calcium.
No direct food interactions known. Maintain adequate hydration; avoid alcohol prior to procedure as it may contribute to dehydration. No specific dietary restrictions, but a light meal before contrast administration is generally advised to reduce nausea.
High-fat meal is recommended to stimulate gallbladder contraction and improve visualization. Avoid low-fat diet on the day of administration as it may impair contrast opacification. No specific food restrictions otherwise. Maintain adequate hydration with water or non-caffeinated beverages.
Minimal excretion into breast milk. M/P ratio unknown. Contrast agent is poorly absorbed orally; unlikely to cause adverse effects in nursing infant. Manufacturer advises discontinuing breastfeeding for 24 hours after administration, though some guidelines consider it safe without interruption. Risk of neonatal hypothyroidism theoretical but negligible.
Limited data; iodinated contrast agents are excreted in breast milk in low amounts. M/P ratio unknown. The American College of Radiology recommends no interruption of breastfeeding following administration, but consider potential for infant hypothyroidism.
No specific dosing adjustment for pregnancy. Use lowest effective dose. Dose based on body weight and examination type; pharmacodynamic changes in pregnancy (increased plasma volume, GFR) may slightly alter contrast clearance but no recommended dose change.
No standard dose adjustment recommended. Use minimum necessary dose. Due to increased renal clearance in pregnancy, consider dose based on body weight and renal function, but no pharmacokinetic data confirm need for adjustment.
Inform your healthcare provider if you have any allergies, especially to iodine or contrast dye.,Tell your doctor if you have kidney problems, diabetes, or take metformin; you may need to temporarily stop metformin.,Drink plenty of fluids before and after the procedure unless instructed otherwise.,Notify your doctor if you are pregnant, breastfeeding, or plan to become pregnant.,Side effects may include warmth, metallic taste, nausea, or injection site pain; usually temporary.
Take Oragrafin Calcium exactly as prescribed, usually the night before your gallbladder X-ray.,You may need to eat a high-fat meal after taking the medication to help your gallbladder contract and improve the imaging study.,Common side effects include diarrhea, nausea, and stomach cramps; these are usually mild and temporary.,Drink plenty of fluids before and after taking this medication to protect your kidneys.,Inform your doctor if you have a history of kidney disease, liver disease, thyroid problems, or high calcium levels.,Avoid taking this medication if you are allergic to iodine-based contrast agents or have hypercalcemia.,This medication may affect thyroid function tests; tell your doctor if you are scheduled for any thyroid tests.,Do not take Oragrafin Calcium if you are pregnant or breastfeeding without consulting your doctor.